Navidea Biopharmaceuticals Inc (OTCPK:NAVB)
$ 0.036 -0.002 (-5.26%) Market Cap: 3.60 Mil Enterprise Value: 998,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q2 2021 Navidea Biopharmaceuticals Inc Earnings Call Transcript

Aug 11, 2021 / 09:00PM GMT
Release Date Price: $1.7 (+2.41%)
Operator

Greetings, and welcome to Navidea Biopharmaceuticals' Second Quarter 2021 Earnings Conference Call and Business update. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Jed Latkin, Chief Executive Officer. Thank you. You may begin.

Jed A. Latkin
Navidea Biopharmaceuticals, Inc. - CEO, COO, CFO & Director

Thank you, Doug. Just want to remind people, this call is being webcast live on our website, ir.navidea.com, and a replay will be made available. Following prepared remarks, we will be conducting a question-and-answer segment. Navidea's Chief Medical Officer, Dr. Mike Rosol; and the company's Vice President of Finance, Erika Eves, will be joining me on the call today.

During the course of this conference call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Navidea's molecular diagnostics and immunotherapeutics, which include clinical and regulatory

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot